biostudies-literatureCools FNational Institute for Health Research (NIHR)e594-e604https://www.ebi.ac.uk/biostudies/studies/S-EPMC9243570biostudies-literatureUnknown9(8)<h4>Background</h4>COVID-19 is associated with inflammation and an increased risk of thromboembolic complications. Prophylactic doses of low-molecular-weight heparin have been used in hospitalised and non-critically ill patients with COVID-19. We aimed to evaluate the efficacy and safety of prophylactic low-molecular-weight heparin (enoxaparin) versus standard of care (no enoxaparin) in at-risk outpatients with COVID-19.<h4>Methods</h4>This open-label, multicentre, randomised, controlled, phase 3b trial (ETHIC) was done at 15 centres in six countries (Belgium, Brazil, India, South Africa, Spain, and the UK). We consecutively enrolled participants aged at least 30 years who had not received a COVID-19 vaccine and had symptomatic, confirmed COVID-19 in the outpatient setting plus at least onThe Lancet. HaematologyThromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial.PMC9243570NF-SI-0611-10273Jacobson BHobbs FDRGibbs HMahajan RMacCallum PThereza Rocha AKaul UKumar PAvhad ASawhney JAbyankar ATurpie AGGETHIC investigatorsLopes RDKakkar AKKayani GRocha ATHaas SGonzales Lama JKormann APMSchellong SAntunes MPieper KAloysius IVirdone SAdams FCools FCapehorn MAgeno WHimmelreich JCLArcelus JIVan Zyl LfalseThromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial.<h4>Background</h4>COVID-19 is associated with inflammation and an increased risk of thromboembolic complications. Prophylactic doses of low-molecular-weight heparin have been used in hospitalised and non-critically ill patients with COVID-19. We aimed to evaluate the efficacy and safety of prophylactic low-molecular-weight heparin (enoxaparin) versus standard of care (no enoxaparin) in at-risk outpatients with COVID-19.<h4>Methods</h4>This open-label, multicentre, randomised, controlled, phase 3b trial (ETHIC) was done at 15 centres in six countries (Belgium, Brazil, India, South Africa, Spain, and the UK). We consecutively enrolled participants aged at least 30 years who had not received a COVID-19 vaccine and had symptomatic, confirmed COVID-19 in the outpatient setting plus at least on2022-01-01T00:00:00Z2022 Aug2026-05-27T21:33:02.613Z2022-07-08T02:00:30.84ZS-EPMC92435703577956010.1016/S2352-3026(22)00173-9